Dr. David Scott Morris, MD

Dr. Morris practices at Gastroenterology and Hepatology Associates, PLLC in Hendersonville, Tennessee.

Dr. Morris' NPI, 1194841452, was assigned on March 21, 2007. Dr. Morris graduated from Vanderbilt University School of Medicine in 2003. Dr. Morris holds Tennessee license MD0000044799.

Dr. Morris' primary practice is Gastroenterology and Hepatology Associates, PLLC, at 107 Glen Oak Blvd, Hendersonville, TN 37075 in Sumner County. The practice phone is (615) 826-0710.

Dr. Morris' primary practice is Gastroenterology and Hepatology Associates, PLLC in Hendersonville, Tennessee. Dr. Morris is also affiliated with TriStar Hendersonville Medical Center. The medical group on file is Urology Associates P.C. Dmand AI also links Dr. Morris to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Morris practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Morris' primary specialty in the NPI Registry, under taxonomy code 208800000X. Dmand AI has Dr. Morris' licenses on file in 2 states: Tennessee and Michigan.

CMS data shows 11,021 Medicare services from Dr. Morris across 38 procedure codes in 2024, for 1,061 Medicare patients. Medicare paid $339,114 for them.

CMS counts 1,061 Medicare patients who saw Dr. Morris in 2024. The largest group is 75 to 84, with 456 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 2% are also on Medicaid. Their average risk score is 1.37, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Morris' median patient age at 72, with 15% women.

In 2024, Dr. Morris wrote 6,174 Medicare Part D claims for 1,224 patients. 71% of them were for generic drugs. CMS names the drug for 5,996 of them, across 38 drugs with 11 or more claims each, at $12,444,627 in total drug cost. In 2023, CMS named 5,469 claims across 41 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Morris for performance year 2024, reported as part of a group. Dr. Morris accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Morris as offering telehealth. CMS counts 15 procedures of prostate resection by Dr. Morris, more than 72% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 17 papers to Dr. Morris, published from 2013 to 2025. 2023 was the busiest year, with 5. The most frequent topics are Prostatic Neoplasms, Genetic Testing and Prostatic Neoplasms, Castration-Resistant. Dr. Morris has published most often in J Urol. Dr. Morris' most frequent co-authors are Alan Haruo Bryce, MD, Laurence H. Belkoff, DO and Christopher M. Pieczonka, MD.

Dmand AI links Dr. Morris to 10 clinical trials, 3 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Non-Muscle Invasive Bladder Neoplasms. Dendreon sponsors the most, 2. Open Payments lists research payments to Dr. Morris that name 1 trial.

CMS Open Payments shows 2,401 general payments to Dr. Morris from 83 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 58% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $238,343. It also lists 2 research payments totaling $466 in 2021, naming 1 clinical trial.

Dr. Morris graduated from Vanderbilt University School of Medicine in 2003.